#1 Clinical Trials Search in Europe

Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Genetically Modified With The Lentiviral Vector Idua Lv, Encoding For The Alpha-L-Iduronidase Cdna

Clinical trials are underway to evaluate a groundbreaking gene therapy called OTL-203 for patients with Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH). This therapy uses the patient’s own stem cells, which are genetically modified to produce a crucial enzyme missing in MPS-IH patients. The trials aim to assess the safety and effectiveness of OTL-203 compared to the current standard treatment of allogeneic hematopoietic stem cell transplantation (allo-HSCT). These studies offer hope for improved outcomes and quality of life for individuals affected by this rare genetic disorder.

Table of Contents

What is OTL-203?

OTL-203 is a new type of medicine called gene therapy. It’s being developed to treat a rare genetic disorder called Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH)[1]. This therapy is different from traditional medicines because it aims to fix the underlying genetic problem that causes the disease.

How does OTL-203 work?

OTL-203 works by using the patient’s own stem cells. Here’s a simple explanation of the process:

  1. Doctors take some of the patient’s blood-forming stem cells from their bone marrow.
  2. In a laboratory, these cells are modified using a special virus (called a lentiviral vector) that carries a healthy copy of the IDUA gene. This is the gene that doesn’t work properly in patients with MPS-IH.
  3. The modified cells, now carrying the healthy gene, are given back to the patient through an intravenous infusion (a drip into a vein).
  4. These cells can then produce the missing enzyme (called alpha-L-iduronidase) that patients with MPS-IH lack[1][2].

What condition does OTL-203 treat?

OTL-203 is designed to treat Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH). This is a rare genetic disorder that affects many parts of the body. People with MPS-IH are missing an important enzyme that helps break down certain substances in the body. Without this enzyme, these substances build up and cause problems in various organs and tissues[1].

Some signs of MPS-IH in young children can include:

  • Frequent ear and respiratory infections
  • Hernias
  • Spine problems
  • Cloudy eyes
  • Enlarged liver and spleen
  • Bone abnormalities
  • Heart valve problems
  • Joint stiffness
  • Cognitive impairment[1]

Clinical Trials for OTL-203

OTL-203 is currently being studied in clinical trials to see how well it works and how safe it is. There are two main studies:

  1. A larger study comparing OTL-203 to the current standard treatment (allogeneic hematopoietic stem cell transplantation or allo-HSCT)[1].
  2. A smaller study looking at the safety and effectiveness of OTL-203 in children with MPS-IH[2].

These studies will help doctors understand how well OTL-203 works compared to current treatments and if it’s safe for patients to use.

Who can receive OTL-203?

Based on the current clinical trials, OTL-203 is being studied in:

  • Children diagnosed with MPS-IH
  • Patients aged from 28 days to 30 months old (in some cases, older children may be considered)[1]
  • In one study, children up to 11 years old[2]

However, there are certain health conditions that might prevent a patient from receiving this treatment. The decision to use OTL-203 would be made by doctors after careful consideration of each patient’s individual situation.

Potential Benefits of OTL-203

Researchers hope that OTL-203 will provide several benefits for patients with MPS-IH:

  • Improved survival rates
  • Better cognitive function (thinking and learning abilities)
  • Improved physical symptoms, such as better joint movement and growth
  • Better quality of life
  • Reduced need for other medical treatments[1]

The clinical trials are designed to measure these outcomes and compare them to current treatments.

Safety Considerations

As with any new treatment, safety is a top priority. The clinical trials for OTL-203 are closely monitoring patients for any side effects or complications. Some areas of focus include:

  • Short-term reactions to the treatment
  • Long-term safety, including checking for any unusual cell growth
  • The body’s immune response to the treatment
  • Any effects on the patient’s blood cells and immune system[1][2]

It’s important to remember that OTL-203 is still an experimental treatment. More research is needed to fully understand its benefits and risks. Patients and families considering this treatment should discuss all options with their healthcare team.

Aspect Details
Treatment OTL-203 (Autologous CD34+ hematopoietic stem cells genetically modified with IDUA lentiviral vector)
Condition Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH)
Trial Phase Phase I/II
Primary Objectives Safety, tolerability, and efficacy compared to standard allo-HSCT
Key Endpoints Event-free survival, enzyme activity, symptom improvement, quality of life
Patient Age 28 days to 11 years (varies by study)
Administration Single intravenous infusion after conditioning
Follow-up Period At least 5 years

FAQ

  • What is OTL-203 and how does it work? OTL-203 is a gene therapy that uses a patient's own stem cells. These cells are modified with a lentiviral vector to produce the enzyme alpha-L-iduronidase, which is missing in patients with MPS-IH. The modified cells are then infused back into the patient, aiming to provide a long-lasting source of the missing enzyme.
  • Who is eligible for these clinical trials? The trials are primarily for children with MPS-IH. One study includes patients aged 28 days to 30 months, while another includes patients up to 11 years old. Specific eligibility criteria include confirmed MPS-IH diagnosis, adequate organ function, and no prior stem cell transplant or gene therapy.
  • How is OTL-203 administered? OTL-203 is given as a one-time intravenous infusion. Before the infusion, patients undergo a process to collect their stem cells and receive conditioning treatment to prepare their body for the gene therapy.
  • What are the main goals of these clinical trials? The primary goals are to evaluate the safety and effectiveness of OTL-203. Researchers will assess event-free survival, changes in enzyme activity, improvements in MPS-IH symptoms, and quality of life compared to standard treatment with allo-HSCT.
  • How long will patients be followed after receiving OTL-203? Patients will be monitored closely for at least 5 years after receiving OTL-203. This long-term follow-up is crucial to assess the therapy's lasting effects and to monitor for any potential long-term side effects or complications.

Ongoing Clinical Trials on Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Genetically Modified With The Lentiviral Vector Idua Lv, Encoding For The Alpha-L-Iduronidase Cdna

  • Study on Gene Therapy with Autologous Stem Cells and Drug Combination for Children with Mucopolysaccharidosis Type I Hurler Variant

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of OTL-203 for Patients with Hurler Syndrome (MPS-IH) Compared to Standard Treatment with Stem Cell Transplantation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Italy The Netherlands

Glossary

  • Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH): A rare genetic disorder caused by the lack of an enzyme called alpha-L-iduronidase, leading to the buildup of certain molecules in the body and causing various health problems.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves modifying a patient's own cells to produce a missing enzyme.
  • Lentiviral vector: A tool used in gene therapy to deliver genetic material into cells. It's derived from a type of virus but modified to be safe for therapeutic use.
  • Hematopoietic stem cells: Immature cells found in bone marrow that can develop into all types of blood cells.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT): A procedure where a patient receives blood-forming stem cells from a genetically similar donor to replace their own stem cells.
  • Alpha-L-iduronidase: An enzyme that is missing or deficient in patients with MPS-IH. It's responsible for breaking down certain complex sugars in the body.
  • Enzyme replacement therapy (ERT): A treatment that provides patients with a manufactured version of the enzyme they're missing or can't produce enough of.
  • Myeloablative conditioning: A preparatory regimen using chemotherapy drugs to destroy the patient's existing bone marrow cells before receiving new stem cells.
  • Event-free survival: A measure of treatment effectiveness that looks at the length of time after treatment that a patient remains free from certain negative events or complications.
  • Replication Competent Lentivirus (RCL): A potential safety concern in gene therapy where the modified virus used to deliver genes could theoretically regain the ability to replicate and cause infection.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-otl-203-for-patients-with-hurler-syndrome-mps-ih-compared-to-standard-treatment-with-stem-cell-transplantation/
  2. http://clinicaltrials.eu/trial/study-on-gene-therapy-with-autologous-stem-cells-and-drug-combination-for-children-with-mucopolysaccharidosis-type-i-hurler-variant/